echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The State Drug Administration has approved the listing of high-volume gene sequencers in China

    The State Drug Administration has approved the listing of high-volume gene sequencers in China

    • Last Update: 2021-01-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Second Generation Sequencing (NGS), also known as large-scale parallel sequencing, can sequence millions or even billions of DNA molecules at the same time, so as to achieve the goal of large-scale high-volume sequencing, currently in the clinical practice of tumor NGS is mainly used to drive gene sequencing, is an important link in the precise diagnosis and treatment of tumors.
    The National Drug Administration has approved the NGS-based NextSeq 550Dx gene sequencer developed by In mena, California, to be officially launched in China for human DNA testing and diagnosis of clinical human samples, and the first NextSeq 550Dx has been successfully installed and commissioned at Huashan Hospital in Shanghai. Since 2017, When NextSeq 550Dx received FDA clinical certification in the United States, it has been clinically certified in more than 40 countries and regions around the world.
    with the continuous development of molecular diagnostic technology and the rapid development of precision medicine construction in China, NGS testing technology is being paid more and more attention by hospitals and clinical testing institutions. In recent years, the introduction of a number of expert consensuses, including the Expert Consensus on the Application of Second Generation Sequencing Technology in The Diagnosis of Precision Medicine on Tumors, has further accelerated the pace of building precision medical testing capabilities in medical institutions. At the same time, the hospital in the process of building the molecular diagnostic laboratory in the hospital for sequencing platform of the volume, cost of use, flexibility and other aspects also put forward higher requirements.
    NextSeq 550 sequencing platform for the first time uses more efficient two-channel chemistry, making exon groups, transcription groups, and genome-wide sequencing a daily research tool, while chip scanning in addition to sequencing capabilities, a versatile and flexible sequencing platform that allows researchers to easily switch between applications to support sequencing projects of different sizes. NextSeq550Dx gene sequencer simplified interface, efficient and accurate sequencing technology, flexible applications to better meet the needs of hospital building molecular laboratories, for different scenarios and needs of hospital NGS testing to bring better solutions, so that precision medicine benefits more patients.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.